{"id":991832,"date":"2026-08-06T23:25:44","date_gmt":"2026-08-07T03:25:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-reports-second-quarter-2026-financial-results-and-provides-business-updates\/"},"modified":"2026-08-06T23:25:44","modified_gmt":"2026-08-07T03:25:44","slug":"solid-biosciences-reports-second-quarter-2026-financial-results-and-provides-business-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-reports-second-quarter-2026-financial-results-and-provides-business-updates\/","title":{"rendered":"Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates"},"content":{"rendered":"
\n

\n –<\/em>
\n
\n \u00a0Duchenne (SGT-003): <\/em>
\n <\/strong>
\n SGT-003 has been generally well tolerated in the Phase 1\/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 –<\/em>\n <\/p>\n

\n – Solid expects to meet with the FDA in late Q4 2026 to discuss the SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003 –<\/em>\n <\/p>\n

\n – Initiation of dosing in the Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind clinical trial commenced in Q2 2026 –<\/em>\n <\/p>\n

\n –\u00a0<\/em>
\n
\n Friedreich\u2019s Ataxia (SGT-212):<\/em>
\n <\/strong>
\n Continued participant screening and enrollment is underway in the Phase 1b FALCON clinical trial; SGT-212 has been well tolerated in the two participants dosed as of August 4, 2026 –<\/em>\n <\/p>\n

\n –\u00a0<\/em>
\n
\n Capital Position:<\/em>
\n <\/strong>
\n Cash, cash equivalents and available-for-sale securities of $377.7 million at June 30, 2026; the Company\u2019s cash runway is anticipated to support late-stage development and early pipeline opportunities into mid-2028 –<\/em>\n <\/p>\n

CHARLESTOWN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the \u201cCompany\u201d or \u201cSolid\u201d), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.<\/p>\n

Bo Cumbo, President and CEO of Solid Biosciences, stated: \u201cOur progress in the first half of 2026 positions us for continued momentum as we approach multiple key clinical and regulatory milestones across our Duchenne, Friedreich\u2019s ataxia and broader precision genetic medicine platform over the next several quarters. In Duchenne, we continue to have confidence in SGT-003\u2019s safety profile, which is achieved using a low-burden, steroid-only immunomodulation regimen. We are also highly encouraged by the strength of the biomarker data we have generated to date, which demonstrates promising biologic activity. As we prepare to analyze 12-month clinical data from initial participants in the INSPIRE DUCHENNE trial, we gain an important opportunity to evaluate the relationship between these biologic signals and clinical outcomes. We look forward to continued engagement with the FDA as we work with urgency to evaluate a potential accelerated approval pathway for SGT-003.\u201d<\/p>\n

Mr. Cumbo continued, \u201cIn FA, we continue to progress SGT-212 with two participants dosed in the FALCON clinical trial, and we look forward to sharing initial data in the first quarter of 2027, which will help inform future development pathways as we aim to bring SGT-212 rapidly to the FA patient community.\u201d<\/p>\n

\n Company Updates<\/strong>\n <\/p>\n

\n Neuromuscular Pipeline<\/strong>
\n
\n SGT-003 Next-Generation Duchenne Muscular Dystrophy (Duchenne) Program<\/em>\n <\/p>\n